Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 ...

Lexicon outlines 2026 milestones as SONATA-HCM enrollment surpasses 50% and cash position is strengthened

Guidance for 2026 operating expenses was narrowed to $100–110 million, from $105–115 million previously. R&D expense expectations shifted lower, while SG&A guidance increased slightly. The company ...